The first-in human applications of the anti-HER2 Nb referred to as 2Rs15d, present high affinity and in vivo tumor targeting to a HER2 epitope distinct from those targeted by trastuzumab and pertuzumab. This evidence concerns the gene ERBB2 and neoplasm.